Gilead Sciences Inc GILD
News
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
Gilead Provides Update on Phase 3 TROPiCS-04 Study
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Gilead Sciences Hosts Inaugural Global Health Equity Summit
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Gilead's FOCUS Program Helps Zero In on Early HIV Detection
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
Gilead Sciences to Present at Upcoming Investor Conferences
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Gilead's quarterly loss is narrower than expected
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
Gilead Sciences Announces First Quarter 2024 Financial Results